【摘要】 目的:对小儿肺炎的两种治疗方案即阿莫西林/克拉维酸连续静脉滴注(A)组和阿莫西林/克拉维酸静脉滴注转口服序贯治疗(B)组的临床疗效及医疗费用进行药物经济学评价。方法:采用前瞻性、随机对照的临床研究方法及药物经济学的最小成本分析法。结果:两组在临床效果、细菌清除率及不良反应发生率方面差异无显著性(P>0.05),但B组的医疗总费用及抗生素费用明显低于A组(P<0.001)。结论:小儿肺炎采用序贯治疗不但安全、有效,而且更加经济合理。更多还原

【Abstract】 Objective To evaluate the pharmacoeconomics in children with pneumonia treated by sequential antimicrobial therapy using amoxicillin/clavulamic-acid. Methods 102 patients with pneumonia were randomly enrolled into two groups: continuous intravenous amoxicillin/clavulamic-acid therapy (Group A, 50 cases) and amoxicillin/clavulamic-acid (intravenous to oral) sequential therapy (Group B, 52 cases). The clinical research methods of prospective and pharmacoeconomical cost-minimization analysis were adopted in this study. Results No significant difference were found in the clinical effect, the bacteria clearance rate and adverse effect occurrence rate between the two groups(P >0.05), but the total expenses and antibiotic cost of the medical treatment of Group B were obviously lower than those of Group A(P< 0.001). Conclusion Sequential antimicrobial therapy for children with pneumonia is not only safe, valid, but more economic reasonable.更多还原